Contemporary outcomes following coronary artery bypass graft surgery for left main disease

Detalhes bibliográficos
Autor(a) principal: Modolo, Rodrigo Gimenez Pissutti, 1980-
Data de Publicação: 2019
Tipo de documento: Artigo
Título da fonte: Repositório da Produção Científica e Intelectual da Unicamp
Texto Completo: https://hdl.handle.net/20.500.12733/1643562
Resumo: Agradecimentos: The SYNTAX trial was supported by Boston Scientific, and the EXCEL trial was funded by Abbott Vascular. Dr. Modolo has received financial support from Sao Paulo Research Foundation (FAPESP) grant number 2017/22013-8. Dr. Banning has been partially funded by the NHS Oxford NIHR Biomedical Research Centre; has received institutional sponsorship for a fellowship from Boston Scientific; and has received lecture fees from Boston Scientific, Medtronic, and Abbott Vascular. Dr. Puskas has been a consultant to Medtronic. Dr. Kappetein is an employee of Medtronic. Dr. Sabik has been a consultant to Medtronic, Edwards Lifesciences, and Sorin; and has served on an advisory board for Medtronic Cardiac Surgery. Dr. Onuma is an employee of Cardialysis. Dr. Stone has been a consultant to Claret, Backbeat, Sirtex, Matrizyme, Miracor, Neovasc, V-wave, Shockwave, Valfix, TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, and Ancora; has received speaker honoraria from Amaranth and Terumo; holds equity in Ancora, Cagent, Qool Therapeutics, Aria, Caliber, Applied Therapeutics, SpectraWave, the MedFocus family of funds, and the BioStar family of funds; is director of SpectraWave; and his employer, Columbia University, receives royalties from sale of the MitraClip manufactured by Abbott Vascular. Prof. Serruys has been a consultant to Abbott, Biosensors, Medtronic, Micell Technologies, QualiMed, SINOMED, St. Jude Medical, Stentys, Svelte, Philips/Volcano, and Xeltis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Michael J. Mack, MD, served as Guest Associate Editor for this paper
id CAMP_7bb669083c40ffb058a7e89fd2ca3c3a
oai_identifier_str oai:https://www.repositorio.unicamp.br/:1173388
network_acronym_str CAMP
network_name_str Repositório da Produção Científica e Intelectual da Unicamp
repository_id_str
spelling Contemporary outcomes following coronary artery bypass graft surgery for left main diseaseDoença da artéria coronarianaCoronary artery diseaseCoronary artery bypass graftDrug-eluting stentsArtigo originalAgradecimentos: The SYNTAX trial was supported by Boston Scientific, and the EXCEL trial was funded by Abbott Vascular. Dr. Modolo has received financial support from Sao Paulo Research Foundation (FAPESP) grant number 2017/22013-8. Dr. Banning has been partially funded by the NHS Oxford NIHR Biomedical Research Centre; has received institutional sponsorship for a fellowship from Boston Scientific; and has received lecture fees from Boston Scientific, Medtronic, and Abbott Vascular. Dr. Puskas has been a consultant to Medtronic. Dr. Kappetein is an employee of Medtronic. Dr. Sabik has been a consultant to Medtronic, Edwards Lifesciences, and Sorin; and has served on an advisory board for Medtronic Cardiac Surgery. Dr. Onuma is an employee of Cardialysis. Dr. Stone has been a consultant to Claret, Backbeat, Sirtex, Matrizyme, Miracor, Neovasc, V-wave, Shockwave, Valfix, TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, and Ancora; has received speaker honoraria from Amaranth and Terumo; holds equity in Ancora, Cagent, Qool Therapeutics, Aria, Caliber, Applied Therapeutics, SpectraWave, the MedFocus family of funds, and the BioStar family of funds; is director of SpectraWave; and his employer, Columbia University, receives royalties from sale of the MitraClip manufactured by Abbott Vascular. Prof. Serruys has been a consultant to Abbott, Biosensors, Medtronic, Micell Technologies, QualiMed, SINOMED, St. Jude Medical, Stentys, Svelte, Philips/Volcano, and Xeltis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Michael J. Mack, MD, served as Guest Associate Editor for this paperAbstract: Although results of percutaneous coronary intervention (PCI) have been steadily improving, whether surgical outcomes have improved over time is not fully elucidated. This study sought to compare the current outcomes of patients undergoing coronary artery bypass grafting (CABG) with prior surgical results, in the context of randomized trials including the left main (LM) coronary artery stem. The authors performed a propensity-matched analysis of patients randomized to CABG in the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) (enrollment period 2005 to 2007) and EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) (enrollment period 2010 to 2014) trials. All patients had left main (LM) disease with or without multivessel disease. Adjustment was based on 15 clinical and angiographic variables, including anatomic SYNTAX score, with a 2:1 ratio for the EXCEL and SYNTAX trials, collectively analyzing 909 subjects (n = 580 and n = 329, respectively). The primary endpoint was the composite of all-cause death, myocardial infarction (MI), stroke, or ischemia-driven revascularization at 3 years. Baseline characteristics, anatomic SYNTAX score, number and types of grafts, and duration of hospitalization for the procedures were similar in both groups. CABG procedures in the EXCEL compared with the SYNTAX trial were more often off-pump (29.6% vs. 15.4%; p < 0.001), and guideline-directed medical therapies were used more frequently in the EXCEL surgical cohort. The primary endpoint occurred in 14.0% and 20.9% (p = 0.008) of patients in the EXCEL and SYNTAX trials, respectively. With the exception of MI (4.1% vs. 3.7%), all nonhierarchical events tended to contribute to the improved outcomes in the more recent trial: all-cause death (5.5% vs. 8.5%), stroke (3.1% vs. 5.1%), and ischemia-driven revascularization (7.1% vs. 9.4%) in the EXCEL and SYNTAX trials, respectively. Over a 5- to 7-year period, significant improvement in event-free survival after surgical revascularization for LM disease at 3 years was noted between the SYNTAX and EXCEL trials, consistent with improving results with cardiac surgery over time. (Synergy Between PCI With Taxus and Cardiac Surgery [SYNTAX]; NCT00114972; Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776)FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPFechadoUNIVERSIDADE ESTADUAL DE CAMPINASModolo, Rodrigo Gimenez Pissutti, 1980-2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.12733/1643562MODOLO, Rodrigo Gimenez Pissutti. Contemporary outcomes following coronary artery bypass graft surgery for left main disease. Journal of the American College of Cardiology. San Diego, CA : Elsevier, 2019.. Vol. 73, no. 15 (Apr., 2019), p. 1877-1886. Disponível em: https://hdl.handle.net/20.500.12733/1643562. Acesso em: 24 mai. 2023.Inglêshttps://repositorio.unicamp.br/acervo/detalhe/1173388reponame:Repositório da Produção Científica e Intelectual da Unicampinstname:Universidade Estadual de Campinas (UNICAMP)instacron:UNICAMPinfo:eu-repo/semantics/openAccess2022-03-31T10:44:02Zoai:https://www.repositorio.unicamp.br/:1173388Repositório InstitucionalPUBhttp://repositorio.unicamp.br/oai/requestreposip@unicamp.bropendoar:2022-03-31T10:44:02Repositório da Produção Científica e Intelectual da Unicamp - Universidade Estadual de Campinas (UNICAMP)false
dc.title.none.fl_str_mv Contemporary outcomes following coronary artery bypass graft surgery for left main disease
title Contemporary outcomes following coronary artery bypass graft surgery for left main disease
spellingShingle Contemporary outcomes following coronary artery bypass graft surgery for left main disease
Modolo, Rodrigo Gimenez Pissutti, 1980-
Doença da artéria coronariana
Coronary artery disease
Coronary artery bypass graft
Drug-eluting stents
Artigo original
title_short Contemporary outcomes following coronary artery bypass graft surgery for left main disease
title_full Contemporary outcomes following coronary artery bypass graft surgery for left main disease
title_fullStr Contemporary outcomes following coronary artery bypass graft surgery for left main disease
title_full_unstemmed Contemporary outcomes following coronary artery bypass graft surgery for left main disease
title_sort Contemporary outcomes following coronary artery bypass graft surgery for left main disease
author Modolo, Rodrigo Gimenez Pissutti, 1980-
author_facet Modolo, Rodrigo Gimenez Pissutti, 1980-
author_role author
dc.contributor.none.fl_str_mv UNIVERSIDADE ESTADUAL DE CAMPINAS
dc.contributor.author.fl_str_mv Modolo, Rodrigo Gimenez Pissutti, 1980-
dc.subject.por.fl_str_mv Doença da artéria coronariana
Coronary artery disease
Coronary artery bypass graft
Drug-eluting stents
Artigo original
topic Doença da artéria coronariana
Coronary artery disease
Coronary artery bypass graft
Drug-eluting stents
Artigo original
description Agradecimentos: The SYNTAX trial was supported by Boston Scientific, and the EXCEL trial was funded by Abbott Vascular. Dr. Modolo has received financial support from Sao Paulo Research Foundation (FAPESP) grant number 2017/22013-8. Dr. Banning has been partially funded by the NHS Oxford NIHR Biomedical Research Centre; has received institutional sponsorship for a fellowship from Boston Scientific; and has received lecture fees from Boston Scientific, Medtronic, and Abbott Vascular. Dr. Puskas has been a consultant to Medtronic. Dr. Kappetein is an employee of Medtronic. Dr. Sabik has been a consultant to Medtronic, Edwards Lifesciences, and Sorin; and has served on an advisory board for Medtronic Cardiac Surgery. Dr. Onuma is an employee of Cardialysis. Dr. Stone has been a consultant to Claret, Backbeat, Sirtex, Matrizyme, Miracor, Neovasc, V-wave, Shockwave, Valfix, TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, and Ancora; has received speaker honoraria from Amaranth and Terumo; holds equity in Ancora, Cagent, Qool Therapeutics, Aria, Caliber, Applied Therapeutics, SpectraWave, the MedFocus family of funds, and the BioStar family of funds; is director of SpectraWave; and his employer, Columbia University, receives royalties from sale of the MitraClip manufactured by Abbott Vascular. Prof. Serruys has been a consultant to Abbott, Biosensors, Medtronic, Micell Technologies, QualiMed, SINOMED, St. Jude Medical, Stentys, Svelte, Philips/Volcano, and Xeltis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Michael J. Mack, MD, served as Guest Associate Editor for this paper
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/20.500.12733/1643562
MODOLO, Rodrigo Gimenez Pissutti. Contemporary outcomes following coronary artery bypass graft surgery for left main disease. Journal of the American College of Cardiology. San Diego, CA : Elsevier, 2019.. Vol. 73, no. 15 (Apr., 2019), p. 1877-1886. Disponível em: https://hdl.handle.net/20.500.12733/1643562. Acesso em: 24 mai. 2023.
url https://hdl.handle.net/20.500.12733/1643562
identifier_str_mv MODOLO, Rodrigo Gimenez Pissutti. Contemporary outcomes following coronary artery bypass graft surgery for left main disease. Journal of the American College of Cardiology. San Diego, CA : Elsevier, 2019.. Vol. 73, no. 15 (Apr., 2019), p. 1877-1886. Disponível em: https://hdl.handle.net/20.500.12733/1643562. Acesso em: 24 mai. 2023.
dc.language.iso.fl_str_mv Inglês
language_invalid_str_mv Inglês
dc.relation.none.fl_str_mv https://repositorio.unicamp.br/acervo/detalhe/1173388
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório da Produção Científica e Intelectual da Unicamp
instname:Universidade Estadual de Campinas (UNICAMP)
instacron:UNICAMP
instname_str Universidade Estadual de Campinas (UNICAMP)
instacron_str UNICAMP
institution UNICAMP
reponame_str Repositório da Produção Científica e Intelectual da Unicamp
collection Repositório da Produção Científica e Intelectual da Unicamp
repository.name.fl_str_mv Repositório da Produção Científica e Intelectual da Unicamp - Universidade Estadual de Campinas (UNICAMP)
repository.mail.fl_str_mv reposip@unicamp.br
_version_ 1766887294705336320

Registros relacionados